Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myotonic Dystrophy Type 1 (DM1): early-phase trial registry
2 of 3 indexed Myotonic Dystrophy Type 1 (DM1) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Myotonic Dystrophy Type 1 (DM1): 3 US clinical trials tracked, 2 recruiting.
Myotonic Dystrophy Type 1 (DM1) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Avidity Biosciences, running 1 of these trials.
Enrollment posture brief
Registry condition myotonic-dystrophy-type-1-dm1
OPEN 2 | RECR 67% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Myotonic Dystrophy Type 1 (DM1) lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myotonic Dystrophy Type 1 (DM1) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myotonic Dystrophy Type 1 (DM1) is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
Dyne Therapeutics
NCT05481879
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Vertex Pharmaceuticals Incorporated
NCT06185764
Global Study of Del-desiran for the Treatment of DM1
Avidity Biosciences
NCT06411288
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Myotonic Dystrophy Type 1 (DM1) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myotonic Dystrophy Type 1 (DM1) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myotonic Dystrophy Type 1 (DM1) page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Myotonic Dystrophy Type 1 (DM1) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Avidity Biosciences sponsors the most Myotonic Dystrophy Type 1 (DM1) trials on record, review their full trial history before evaluating a specific study. See Avidity Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myotonic Dystrophy Type 1 (DM1) condition card totals 3 registered trials; most-linked intervention Placebo; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.